NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating...

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review - Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the use of Foresight CLARITY™ for patient enrollment in the ALPHA3 clinical...

Foresight Diagnostics to Present New Data on Foresight CLARITY™ MRD in Early-Stage Breast Cancer at ESMO Congress 2024 BOULDER, Colo., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection, today announced an upcoming presentation...

Foresight Diagnostics Expands Series B Financing to $73.75 Million to Advance the Foresight CLARITY™ MRD Platform BOULDER, Colo., July 30, 2024 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease...